BioCentury | Nov 22, 2020
Regulation

Distribution of Regeneron’s COVID-19 antibody cocktail to begin Tuesday

...more risk factor.Recommendations from an independent DMC in late October suggested the optimal window for therapeutic antibodies’...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...by inducing patients’ immune systems to manufacture therapeutic antibodies in...
BioCentury | Nov 7, 2020
Emerging Company Profile

IgGenix: antibody engineering for food allergies

IgGenix is pairing single-cell sequencing with antibody engineering to create a new class of food allergy therapies that selectively suppresses allergen-triggered immunity while sidestepping the risky steps of desensitizing immunotherapy.  The company launched in August with...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive...
BioCentury | Jul 18, 2020
Product Development

COVID-19 mAb developers weigh master protocols as they set clinical strategies

...the primary mode for prophylaxis, but that’s still a little ways away and we think therapeutic antibodies...
BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | Apr 24, 2020
Product Development

Upbeat Lilly earnings come with positive psoriasis results, delays for two autoimmune programs

Lilly announced positive Phase III data for autoimmune disease candidate mirikizumab and attributed a bump in revenue, adjusted guidance and trial delays to the COVID-19 pandemic. As part of its 1Q20 earnings, Eli Lilly and...
BioCentury | Apr 4, 2020
Finance

Investors are seeking only one thing: a sign the pandemic tide is shifting

The usual clinical and commercial catalysts are taking a back seat in the second quarter as buysiders are almost solely focused on COVID-19 milestones that will stabilize the market. On the other hand, the virtual...
BioCentury | Apr 4, 2020
Translation in Brief

HiFiBiO’s platform for antibody screening applied to COVID-19; plus Fundamental’s peptide mimetics for stroke, and BMS-IONpath

HiFiBiO’s antibody discovery platform HiFiBiO Therapeutics has described in a Nature Biotechnology article its CelliGO microfluidics platform for high-throughput screening of antibodies secreted from single B cells. The company is using the platform to screen...
BioCentury | Jan 25, 2020
Product Development

The race is on to develop therapies and vaccines for the coronavirus outbreak

Public release of the genetic sequence of the coronavirus first detected in Wuhan, China acted as a starter pistol, setting off a race to develop medical countermeasures. Beyond the potential for containing and hopefully eradicating...
Items per page:
1 - 10 of 388
BioCentury | Nov 22, 2020
Regulation

Distribution of Regeneron’s COVID-19 antibody cocktail to begin Tuesday

...more risk factor.Recommendations from an independent DMC in late October suggested the optimal window for therapeutic antibodies’...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...by inducing patients’ immune systems to manufacture therapeutic antibodies in...
BioCentury | Nov 7, 2020
Emerging Company Profile

IgGenix: antibody engineering for food allergies

IgGenix is pairing single-cell sequencing with antibody engineering to create a new class of food allergy therapies that selectively suppresses allergen-triggered immunity while sidestepping the risky steps of desensitizing immunotherapy.  The company launched in August with...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive...
BioCentury | Jul 18, 2020
Product Development

COVID-19 mAb developers weigh master protocols as they set clinical strategies

...the primary mode for prophylaxis, but that’s still a little ways away and we think therapeutic antibodies...
BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | Apr 24, 2020
Product Development

Upbeat Lilly earnings come with positive psoriasis results, delays for two autoimmune programs

Lilly announced positive Phase III data for autoimmune disease candidate mirikizumab and attributed a bump in revenue, adjusted guidance and trial delays to the COVID-19 pandemic. As part of its 1Q20 earnings, Eli Lilly and...
BioCentury | Apr 4, 2020
Finance

Investors are seeking only one thing: a sign the pandemic tide is shifting

The usual clinical and commercial catalysts are taking a back seat in the second quarter as buysiders are almost solely focused on COVID-19 milestones that will stabilize the market. On the other hand, the virtual...
BioCentury | Apr 4, 2020
Translation in Brief

HiFiBiO’s platform for antibody screening applied to COVID-19; plus Fundamental’s peptide mimetics for stroke, and BMS-IONpath

HiFiBiO’s antibody discovery platform HiFiBiO Therapeutics has described in a Nature Biotechnology article its CelliGO microfluidics platform for high-throughput screening of antibodies secreted from single B cells. The company is using the platform to screen...
BioCentury | Jan 25, 2020
Product Development

The race is on to develop therapies and vaccines for the coronavirus outbreak

Public release of the genetic sequence of the coronavirus first detected in Wuhan, China acted as a starter pistol, setting off a race to develop medical countermeasures. Beyond the potential for containing and hopefully eradicating...
Items per page:
1 - 10 of 388